Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

With Positive Boceprevir Data In Hand, Merck Prepares NDA Submission

This article was originally published in The Pink Sheet Daily

Executive Summary

Two Phase III trials evaluating the protease inhibitor in HCV met their primary endpoints but the real test is how boceprevir stacks up to Vertex's telaprevir.

You may also be interested in...



Vertex And Merck Neck-To-Neck In HCV Race

Vertex gets priority review for its protease inhibitor weeks after Merck announces its own accelerated timeline.

Vertex And Merck Neck-To-Neck In HCV Race

Vertex gets priority review for its protease inhibitor weeks after Merck announces its own accelerated timeline.

Merck May Be Positioned For First Approval Of A Protease Inhibitor In HCV

The pharma announced Jan. 6 that boceprevir has been accepted for priority review by FDA, making an early-May action date likely.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071130

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel